LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    EuropaBio 2026 AGM Appoints New Board Members and Expands Membership

    18/06/2026

    PRESS RELEASE

    Brussels, 18 June 2026

    EuropaBio’s 2026 Annual General Meeting (AGM), held on 18 June 2026, confirmed the appointment of new Board members and welcomed new association members from across biotechnology ecosystems and international locations. The AGM takes place in EuropaBio’s 30th anniversary year, with 2026 marking three decades since its establishment in 1996.

    EuropaBio welcomes the new Board representatives, who will bring leadership from across their respective sectors within biotechnology, and will prove invaluable in guiding the association going forward.

    • Hugh Pullen representing Novartis, elected Chair of the Healthcare Biotechnology Council and appointed as a Board Member
    • Sabrina Conti representing Merck, elected Vice-Chair of the Healthcare Biotechnology Council
    • Frédéric Druck representing bio.be, appointed as a Board Member
    • Maciej Gajewski representing Ipsen, appointed as a Board Member
    • Lauren Kjeldsen representing Evonik, appointed as a Board Member
    • Chris Molloy representing BIA, appointed as a Board Member
    • Michael Morrissey representing MSD, appointed as a Board Member

    Additionally, 19 new member companies and associations were confirmed during the AGM, further strengthening EuropaBio’s diverse and representative membership across the European biotechnology ecosystem. EuropaBio welcomes Apellis International GmbH, The Baker Company, Biotech Austria, BeneMeat Technologies a.s., Bio-based and Biodegradable Industries Association (BBIA), the Association of Biopharmaceutical Manufacturers in Latvia (BRAL), CrystalsFirst GmbH, Ecolab, European CRO Federation (EUCROF), Grittgene Therapeutics, the Hungarian Biotechnology Association (Magyar Biotechnológiai Szövetség), Luxembourg Institute of Science and Technology (LIST), Nestlé, Niconex Medical Ltd, Pivot Bio, Ribbon Bio GmbH, Slovenia Biotech Hills, Technovative Solutions Limited, and Vial.

    Dr Claire Skentelbery, Director General of EuropaBio commented “2026 marks a pivotal year for biotechnology and EuropaBio is at the heart of the EU’s legislative progress. We are delighted our member community continues to grow and diversify, ensuring that all sectors and all actors are part of building its future.”

    Press Release – EuropaBio 2026 AGM Appoints New Board Members and Expands Membership


    Download
    Share
    Adrian Lincoln
    Adrian Lincoln

    Related posts

    16/06/2026

    EFIB 2026 Den Haag Statement


    Read more
    10/06/2026

    EuropaBio calls for ambitious, cross-sectoral Biotech Act II to unlock Europe’s biomanufacturing potential


    Read more
    05/06/2026

    The Baker Company Benelux BV joins EuropaBio: Advancing cell culture and lab safety technologies


    Read more

    Important links

    • EuropaBio 2026 AGM Appoints New Board Members and Expands Membership
    • EFIB 2026 Den Haag Statement

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.